[
  {
    "ts": null,
    "headline": "Moderna (NasdaqGS:MRNA) Expands AI-Ready Collaboration With Benchling For R&D Transformation",
    "summary": "Moderna (NasdaqGS:MRNA) recently expanded its collaboration with Benchling, enhancing its digital infrastructure to foster research innovation. Despite this positive development, Moderna's share price fell 6% over the past month. This decline occurred amid broader market gains, with major U.S. indexes like the Nasdaq and S&P 500 climbing due to optimism around U.S.-UK trade deals and rising cryptocurrency prices. However, Moderna's report of decreased revenues and a significant net loss in Q1...",
    "url": "https://finnhub.io/api/news?id=e572eefd0e0ba9f58e7bf9d58066590e6555f3e5d244e1bdf969f4eac3f6ac40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746727062,
      "headline": "Moderna (NasdaqGS:MRNA) Expands AI-Ready Collaboration With Benchling For R&D Transformation",
      "id": 134336410,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (NasdaqGS:MRNA) recently expanded its collaboration with Benchling, enhancing its digital infrastructure to foster research innovation. Despite this positive development, Moderna's share price fell 6% over the past month. This decline occurred amid broader market gains, with major U.S. indexes like the Nasdaq and S&P 500 climbing due to optimism around U.S.-UK trade deals and rising cryptocurrency prices. However, Moderna's report of decreased revenues and a significant net loss in Q1...",
      "url": "https://finnhub.io/api/news?id=e572eefd0e0ba9f58e7bf9d58066590e6555f3e5d244e1bdf969f4eac3f6ac40"
    }
  },
  {
    "ts": null,
    "headline": "Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025",
    "summary": "CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41st Annual Strategic Decisions Conference (SDC), on Thursday, May 29th at 10:00am ...",
    "url": "https://finnhub.io/api/news?id=5fd35e57a77e5b01a52d90adf7599b4b0f4906b88c1e12d7d728ba439476abb5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746702000,
      "headline": "Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025",
      "id": 134325689,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41st Annual Strategic Decisions Conference (SDC), on Thursday, May 29th at 10:00am ...",
      "url": "https://finnhub.io/api/news?id=5fd35e57a77e5b01a52d90adf7599b4b0f4906b88c1e12d7d728ba439476abb5"
    }
  },
  {
    "ts": null,
    "headline": "Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks",
    "summary": "Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics earnings season.",
    "url": "https://finnhub.io/api/news?id=0c492f845bc4549298692cf3a6a35971835b4c59dd71bcde1b69b5d9c8a427cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746675186,
      "headline": "Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks",
      "id": 134325253,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics earnings season.",
      "url": "https://finnhub.io/api/news?id=0c492f845bc4549298692cf3a6a35971835b4c59dd71bcde1b69b5d9c8a427cb"
    }
  },
  {
    "ts": null,
    "headline": "Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)",
    "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta Therapeutics (NASDAQ:SRPT).",
    "url": "https://finnhub.io/api/news?id=c839c0ccb4be48012897fc8ea8c1e692a2b6eaaeb3bffa442c92a5f66465d8e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746675065,
      "headline": "Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)",
      "id": 134325606,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta Therapeutics (NASDAQ:SRPT).",
      "url": "https://finnhub.io/api/news?id=c839c0ccb4be48012897fc8ea8c1e692a2b6eaaeb3bffa442c92a5f66465d8e2"
    }
  }
]